Because cisplatin‐based chemotherapy mainly induces double‐strand breaks and apoptosis in tumour cells, suppressing the ZBTB11/DDX1 signalling axis may increase the cisplatin sensitivity of BC cells. Here, ZBTB11 is linked to breast cancer.